Morepen Laboratories Limited — Investor Meet, 19-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

**1. Financial Performance:** Morepen Laboratories reported a revenue of INR 443 crores for the quarter, a 4% year-over-year increase. The EBITDA surged 33% to INR 49 crores, while the profit after tax soared 64% to INR 35 crores, reflecting strategic cost management. This led to an impressive EPS of INR 0.65, up 55% from the previous year, with a trailing twelve-month EPS of INR 2.53.

**2. Future Outlook and Growth Drivers:** Management emphasized a strategic pivot from API-centric operations to a stronger consumer-facing approach, targeting significant growth in the medical devices and branded consumer health sectors. The aim is to achieve a revenue target of INR 5,000 crores by 2030, leveraging a projected CAGR of 20% driven by product innovation and market expansion.

**3. Order Book and Operational Updates:** The company is currently executing a significant expansion plan funded by a recent INR 200 crores QIP, allocating INR 123 crores towards capex. New machinery orders have been placed, with civil work progressing, expected to significantly boost production capacity in the next 18-24 months.

**4. Analyst Q&A Insights (Detailed):**

- **Revenue and Profitability:** Analysts queried the decline in API sales, to which management attributed a strategic shift to prioritize higher-margin products over volume sales in low-yield markets.

- **Market Position and Competitive Landscape:** Concerns over competition and market share were addressed, with management confident about retaining strong customer relationships while redefining pricing strategies to enhance margins.

- **Operational Challenges or Risks:** Supply chain challenges were acknowledged, particularly in the medical devices segment, which faced production constraints but should normalize due to recent investments.

- **Capex and Capital Allocation:** Management was confident that the ongoing capex expansion will support future growth, aiming for improved profitability by focusing on high-value drugs.

- **Strategic Priorities and Long-Term Vision:** The commitment to transitioning towards a B2C model, increasing brand visibility alongside expanding their medical devices portfolio, was a prominent theme.

**5. Market or Regulatory Updates:** The company gained regulatory approval for exporting certain medical devices to the US and Canada, opening significant market opportunities. Attendance at major exhibitions indicates proactive efforts in expanding international reach.

**6. Strategic Focus Areas:** A heightened focus on consumer-driven growth, cost control, and brand development was evident. Management’s confidence in navigating market dynamics while maintaining strong margins indicates a strategic pivot toward sustainable growth.

**7. Investor Insight:** The solid performance and strategic outlook suggest a favorable trajectory. Given the emphasis on profitability and market expansion, this could align well with a ‘buy’ stance for investors keen on long-term value creation. Management’s focus on robust operational efficiencies and increased capex points toward a confident growth forecast, inviting further support from stakeholders.